




RealRate

PHARMACEUTICAL 2021

Syros Pharmaceuticals Inc
Rank 101 of 394

SYROS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Syros Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syros Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Syros Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 345%, being 88% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	178,557
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,624
Liabilities, Non-Current	0
Other Assets	20,480
Other Compr. Net Income	-1,765
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	15,093
Property and Equipment	14,213
Research and Development	76,065
Selling, General and Administrative Expense	21,325

Output Variable	Value in 1000 USD
Assets	213,250
Liabilities	28,624
Expenses	97,390
Revenues	15,093
Stockholders Equity	184,626
Net Income	-82,297
Comprehensive Net Income	-83,180
BaseVar	178,061
ECR before LimitedLiability	264%
Economic Capital Ratio	345%